These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 34371443)

  • 21. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world data for precision cancer medicine-A European perspective.
    Christopoulos P; Schlenk R; Kazdal D; Blasi M; Lennerz J; Shah R; Budczies J; Malek N; Fröhling S; Rosenquist R; Schirmacher P; Bozorgmehr F; Kuon J; Reck M; Thomas M; Stenzinger A
    Genes Chromosomes Cancer; 2023 Sep; 62(9):557-563. PubMed ID: 36852573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world Data and Evidence to support a switch in status from Prescription drug to Over the Counter drug as applied by the EMA, the US FDA, the MHRA, and the BfArM.
    Kühler TC; Ateka A; Lassoued Z; Routhier FX; Mékary-Sawaya S
    Clin Ther; 2024 Mar; 46(3):208-216. PubMed ID: 38278703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
    Vokinger KN; Kesselheim AS
    BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries.
    Green AK; Curry M; Trivedi N; Bach PB; Mailankody S
    JAMA Netw Open; 2021 Feb; 4(2):e210030. PubMed ID: 33625507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.
    Naci H; Zhang Y; Woloshin S; Guan X; Xu Z; Wagner AK
    Lancet Oncol; 2024 Jun; 25(6):760-769. PubMed ID: 38754451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
    Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
    JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
    Jacquet E; Kerouani-Lafaye G; Grude F; Goncalves S; Lorence A; Turcry F; Brunel L; Belgodere L; Monard A; Guyader G; Boudali L; Albin N
    Eur J Cancer; 2021 May; 149():82-90. PubMed ID: 33838392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis.
    Leo CP; Hentschel B; Szucs TD; Leo C
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32069837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
    Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
    Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
    Naci H; Davis C; Savović J; Higgins JPT; Sterne JAC; Gyawali B; Romo-Sandoval X; Handley N; Booth CM
    BMJ; 2019 Sep; 366():l5221. PubMed ID: 31533922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential negative impact of reputed regulators' decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis.
    Durán CE; Cañás M; Urtasun M; Elseviers M; Vander Stichele R; Christiaens T
    PLoS One; 2021; 16(7):e0254585. PubMed ID: 34255795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency.
    Szymański P; Weidinger F; Lordereau-Richard I; Himmelmann A; Arca M; Chaves J; Lee C; Jonker C; Kotecha D; O'Kelly J; Plueschke K; Ryś A; Segec A; Wallentin L; Veltrop R; James S
    Eur Heart J Qual Care Clin Outcomes; 2023 Feb; 9(2):109-118. PubMed ID: 36746430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.
    Hwang TJ; Ross JS; Vokinger KN; Kesselheim AS
    BMJ; 2020 Oct; 371():m3434. PubMed ID: 33028575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016-2021.
    Wang X; Dormont F; Lorenzato C; Latouche A; Hernandez R; Rouzier R
    J Cancer Policy; 2023 Mar; 35():100403. PubMed ID: 36646208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views.
    Tafuri G; Stolk P; Trotta F; Putzeist M; Leufkens HG; Laing RO; De Allegri M
    Ann Oncol; 2014 Jan; 25(1):265-9. PubMed ID: 24356637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.
    Boesen K; Gøtzsche PC; Ioannidis JPA
    Epidemiol Psychiatr Sci; 2021 Apr; 30():e35. PubMed ID: 33926608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis.
    Farina A; Moro F; Fasslrinner F; Sedghi A; Bromley M; Siepmann T
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00816. PubMed ID: 34232554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
    Chen EY; Raghunathan V; Prasad V
    JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.